Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieve a durable complete response. Furthermore, ...
Solid tumors have been a tougher nut to crack for CAR T cells than B-cell cancers, for two main reasons. Solid tumors have an inhibitors microenvironment that has made it difficult to get durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results